Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (DBD) Fair Value & Analysis
Healthcare · VN · Market cap 4.7T VND
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 5 days ago
Fair value updated Jun 24, 2026 — revised from 52,356 VND to 52,388 VND (+0.1%) since Jun 23, 2026. Share price +1.2% over the past month.
Price vs Fair Value (12 months)
12‑month range 46,308 VND – 54,259 VND · fair‑value band 32,609 VND – 71,374 VND · the 50,500 VND price screens below the 52,388 VND fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (DBD) currently trades at 50,500 VND, while our model-based Fair Value estimate is 52,388 VND — implying the stock looks roughly 3.7% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company generated revenue of 1.9T VND at a net margin of 15.6%. Revenue grew 1.6% year over year. It earns a return on equity of 16.4%. Net debt stands at 20.4B VND. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company manufactures and trades in pharmaceuticals and medical equipment in Vietnam. It offers antibiotics; anticancer drugs; hemodialysis solutions; hepatobiliary drugs; analgesic and antipyretic drugs; drugs for muscles, bones, and joints; antihistamine anti-allergy drugs; ear, eye, nose, and throat drops; cardiovascular drugs; nervous system drugs; vitamins and minerals; endocrine hormones; respiratory drugs; antifungal and antiviral drugs; dermatologic drugs; antidotes; and drugs for treating lipid disorders. The company also provides automatic herbal medicine brewing stoves, distilled water tanks, hand sanitizers, medical solid waste incinerators, water distillers, washing machines, eye drop bottle washing machines, clothes dryers, autoclave machines, and drying and microclimate cabinets. In addition, it engages in the wholesale and retail sale of medicines, medicinal herbs, and medical equipment; and production of medi…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company reported revenue of 1.9T VND in FY2025 versus 1.6T VND in FY2021, a compound +4.6%/yr. Reported net income was 292B VND in FY2025, compounding +11.5%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.08 | ¥26.59 | -44% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Swedish Orphan Biovitrum AB SOBI | kr 446.60 | kr 234.19 | -48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (DBD) undervalued?
What is the fair value of DBD?
What is the quality score of DBD?
What is the revenue of Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (DBD)?
What is the net profit margin of DBD?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.